Protecting Patients from Harm: Terfenadine and Potential Drug Therapy Interactions

Abstract

Communication of drug interactions has been the focus of reports surrounding the use of terfenadine. Two studies reported in the literature indicated that coprescription events between terfenadine and contraindicated drugs occurred despite communications to health professionals regarding potential harm. Recent studies have found that pharmacists frequently dispense such drug combinations without concern or appropriate counseling. Throughout 1996, reports in journals and the public press created concern over drug interactions and the practice of pharmacy. The terfenadine case study highlights weak links in the chain of communication of serious medical information. Early warnings to health professionals did not result in the elimination of potential events. Additional communications decreased the rate of coprescription events but did not eliminate them. Current investigations show that these events continue. All health care professionals involved in the distribution of pharmaceuticals should use the experiences related to terfenadine as a means to improve their handling of drug interaction and other medical information.